UK's food labelling needs a complete overhaul to combat obesity crisis, health coach claims
He praised the black warning labels on ultra-processed foods in Chilean supermarkets, which has led to a measurable decline in sales of these marked products.
4
4
Steve, founder of a health app called Clubwell, said: 'Our food labelling system does little to deter Brits away from unhealthy options.
'Although well-intentioned, the current traffic light system fails to clearly inform consumers of the health risks associated with ultra-processed foods.
'The system is based on manufacturer-designed portion sizes which are so unrealistic they border on fantasy. When did you last eat just half a biscuit or a single square of chocolate?
'Chile's approach is simple and effective. The introduction of stark black warning labels on foods high in sugar, salt, calories and saturated fat has reduced sales of harmful foods, improved public awareness, and contributed towards a drop in childhood obesity.
'I would expect a similar model in Britain to reflect these results.'
Since Chile's policy was introduced, purchases of sugary foods were reportedly cut by as much as 25 per cent.
Sales of ultra-processed foods with the labels in school kiosks dropped from 90 per cent to 15 per cent within six months of the law's introduction.
Britain currently leads Europe in ultra-processed food consumption, with these products making up over 50 per cent of all food purchases.
Steve added: ' Obesity not only increases the risk of heart disease, Type 2 Diabetes and several other diseases, but it also places huge pressure on the NHS and the UK economy.
'Changing our food labelling system and limiting sales of UPFs is a vital step towards tackling this spiralling obesity crisis.
'Addressing the root of the issue is far more effective in the long-term. We shouldn't simply be relying on weight loss jabs to solve the obesity epidemic.
'Transparent labelling would empower consumers to make informed choices and reduce dependence on pharmaceutical solutions.
'The food industry has resisted change, but the evidence is clear, bold labels work.
'I urge the UK government to implement clear warning labels, restrictions on marketing to children and removal of junk food from schools.'
Steve, who has created £100 million companies during his award-winning commercial career before becoming a respected health coach, is launching the FREE Clubwell app later in the year to encourage users to keep track of their metabolic health to prevent future health issues related to insulin resistance.
4
4
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
39 minutes ago
- Daily Mail
I've been using Mounjaro for nearly a year and have lost five stone without any nasty side-effects... but this is why the new fat jab trend has left me sickened: JENNI MURRAY
What is wrong with pet owners in this country that they'd let the animals in their care become dangerously obese? I've owned dogs all my life – 11 in total – as well as seven cats and I've never allowed a single one to become fat. My old cross-breed corgi, who was my friend through my childhood, would have eaten anything I put in front of him. And there's the clue. Feeding an animal has to be done in a well-informed and disciplined manner.
Daily Mail
an hour ago
- Daily Mail
Physiotherapist reveals why you should NEVER cross your legs on a flight
It can be difficult to get comfortable during plane journeys, with small seats and little leg room there is often not much room for movement. Many passengers cross their legs on flights, but AXA Health physiotherapist Bethany Tomlinson has warned against the common seating position. According to research, more than one in 10 adults in the UK experience joint issues. However, this pain could be worsened by long periods of inactivity sitting on aeroplanes. Bethany explains the risks that can come with sitting cross-legged during a flight. She warns: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' Instead, the expert advises keeping legs elevated and choosing different relaxing positions. 'If there's a footrest under the seat in front of you, use this to keep your legs slightly elevated,' she adds. 'Make sure to relax your shoulders and support your back by sitting back into the plane seat whilst you wait.' To the millions of Brits jetting off this summer, Bethany urges travellers to prepare for the journey to avoid causing strain on joints. One in three Brits experience stiffness in their knees, and lack of movement or staying in the same position can only worsen this. Bethany says: 'Catching flights this summer could turn into an endurance test for our joints, so prepare for every flight like it could be long-haul. 'Knowing how to position your body and doing exercises when seated to keep your joints moving is essential.' Another way to ease joint discomfort is by standing in a certain position, Bethany explains. She adds: 'When standing up, shift weight between your feet, keep knees slightly bent and do light stretches to avoid too much pressure on your lower body.' For longer flights, Bethany shares what routine passengers should keep to in order to ensure their joints are healthy. Bethany warns passengers: 'Avoid crossing your legs in your plane seat as this will impact blood flow and increase the risk of developing deep vein thrombosis (DVT).' (stock) 'Flyers need to move their body every 1-2 hours on flights to keep joints mobilised. 'Being in the same position for hours can lead to stiff and swollen joints, particularly the knees, ankles and hips. 'Seated exercises whilst in the air will help boost circulation, and reduce the risk of DVT, a common type of blood clot that can form during long periods of sitting.' The physiotherapist shared a range of mobilising exercises that passengers can easily do from their plane seat, including neck stretches, shoulder rolls and knee hugs.
The Independent
2 hours ago
- The Independent
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
